*Acinetobacter baumannii*, a ubiquitous aerobic, glucose-non-fermenting, gram-negative bacterium, is able to survive on inanimate objects or fomites and colonize the human body. During the last 2 decades, this microorganism has been the etiological agent of serious opportunistic infections and nosocomial outbreaks \[[@B1]\]. In particular, nosocomial infections and colonization of multidrug-resistant (MDR) *A. baumannii* strains have been reported globally, mainly in intensive care units (ICUs). Most MDR *A. baumannii* strains are highly resistant to many antimicrobial agents, and therefore, therapeutic options are increasingly limited. Because of these reasons, it should be emphasized that preventing and controlling the dissemination of these strains is very important \[[@B2]-[@B4]\]. *A. baumannii* is not only a nosocomial pathogen in adults, but it is also responsible for neonatal infections, generally causing pneumonia \[[@B5]\].

Although numerous nosocomial infections caused by MDR *A. baumannii* strains are appearing rapidly worldwide, especially in the ICUs, there is a relative paucity of data associated with its dissemination in neonatal ICUs (NICUs) in Korea. In the present study, we aimed to determine the clonal relationships among clinical isolates obtained from an NICU of a university hospital in Daejeon, Korea. In addition, the genetic basis for multidrug resistance was investigated with special focus on carbapenemases, aminoglycoside-modifying enzymes (AMEs), 16S rRNA methylase, and mutations in the *gyrA* and *parC* genes.

A total of 8 consecutive and non-duplicate MDR *A. baumannii* strains were collected from the NICU of the university hospital in Daejeon, Korea, during the period from October 2011 to February 2012 ([Table 1](#T1){ref-type="table"}). *A. baumannii* strains were identified using the Vitek 2 automated instrument ID system (BioMérieux, Marcy l\'Etoile, France) and by sequencing the partial *rpoB* housekeeping gene, as described previously \[[@B6]\].

The minimum inhibitory concentrations (MICs) for *A. baumannii* isolates of amikacin, gentamicin, ceftazidime, cefepime, imipenem, and ciprofloxacin were determined using Etest (AB Biodisk, Solna, Sweden). The results obtained were interpreted as per the criteria approved by the CLSI guidelines \[[@B7]\]. Escherichia coli ATCC 25922 was used as a reference strain. Whole cell (genomic) DNA for PCR templates was obtained from each target strain by using a genomic DNA purification kit (SolGent, Daejeon, Korea), according to the manufacturer\'s instructions. Two multiplex PCR assays were used as previously described \[[@B8]\] to identify members of European (EU) clones I and II. The Oxford multilocus sequence typing (MLST) scheme \[[@B9]\], which uses 7 housekeeping genes (*gltA*, *gyrB*, *gdhB*, *recA*, *cpn60*, *gpi*, and *rpoD24*), was used to determine the sequence types (STs). An ST number was assigned by comparing the allele sequences to those in the MLST database (<http://pubmlst.org/abaumannii/>). Epidemiological typing of isolates was performed by repetitive extragenic palindromic sequence (REP)-PCR \[[@B10]\].

All *A. baumannii* isolates were subjected to PCR and sequencing assays for detecting the determinants of antimicrobial resistance and for identifying the mutations associated with fluoroquinolone resistance. Specific primers and PCR conditions for detection of antimicrobial resistance determinants were as described in a previous study \[[@B11]\]. The amplicons were purified with a PCR purification kit (SolGent) and sequenced using a BigDye Terminator Cycle Sequencing Kit (PE Applied Biosystems, Foster City, CA, USA) and an ABI PRISM 3730XL DNA analyzer (PE Applied Biosystems).

A total of 8 *A. baumannii* isolates were identified on the basis of their *rpoB* gene analysis. Although all the isolates were susceptible to imipenem, they showed resistance to amikacin, gentamicin, ceftazidime, cefepime, and ciprofloxacin ([Table 2](#T2){ref-type="table"}). These isolates belonged to EU clone II and carried allele 66 of the intrinsic *bla*~OXA-51~-like genes, which agrees with their assignment to EU clone II. They were all identified as ST357 (1-12-3-2-2-145-3) by MLST analysis. To determine the clonality of all 8 *A. baumannii* isolates, REP-PCR was carried out using genomic DNA. They all displayed the same REP-PCR type ([Fig. 1](#F1){ref-type="fig"}). Our results suggest that ST357 *A. baumannii* strains isolated during instances of nosocomial infections or colonization in the NICU of the university hospital in Daejeon, Korea, belonged to EU clone II. Nosocomial infections or colonization due to ST357 *A. baumannii* isolates have not been detected in Korea previously. Thus, to the best of our knowledge, this is the first report of ST357 MDR/carbapenem-susceptible *A. baumannii* strains causing NICU nosocomial infections in Korea. This result suggests that not only MDR/carbapenem-resistant strains but also MDR/carbapenem-susceptible isolates act as major causes of nosocomial outbreaks, especially in the NICU, in Korea.

To define the genetic basis of MDR *A. baumannii* isolates by detecting antimicrobial resistance determinants, PCR and PCR mapping experiments were performed. All 8 *A. baumannii* isolates had the combination of AMEs encoded by *aac(6\')-Ib*/*aph(3\')-Ia* and 16S rRNA methylase encoded by *armA*. They showed high-level resistance to amikacin (MIC ≥256 mg/L) and gentamicin (MIC ≥1,024 mg/L). Unlike AMEs, which varies in their substrate ranges, 16S rRNA methylases confer high-level resistance to almost all clinically important aminoglycosides \[[@B12], [@B13]\]. In addition, they all had sense mutations at the 83rd residue (serine to leucine) in *gyrA* and at the 80th residue (serine to leucine or tryptophan) in *parC* and had high-level ciprofloxacin resistance (MIC~50~ ≥32 mg/L). A major mechanism of fluoroquinolone resistance in gram-negative bacteria involves changes in the structure of DNA gyrase and DNA topoisomerase IV \[[@B14]\]. Notably, amino acid substitutions in both the *GyrA* and *ParC* polypeptides are consistent with a high-level fluoroquinolone-resistant phenotype \[[@B15]\]. In this study, all 8 isolates harbored sense mutations in both gyrA and parC and showed high-level resistance to ciprofloxacin. In contrast, carbapenem-resistance genes, including metallo-β-lactamase genes and *bla*~OXA-23~-, *bla*~OXA-24~-, and *bla*~OXA-58~-like genes, were not found in this study.

Carbapenems are frequently the drug of choice to treat *A. baumannii* infections, and carbapenem resistance is, in itself, sufficient to define a highly resistant phenotype. Although nosocomial infections and colonization due to MDR *A. baumannii* have been reported worldwide, previous studies were focused primarily on carbapenem-resistant strains \[[@B12], [@B16]\]. Consequently, MDR/carbapenem-susceptible isolates have been rarely recovered worldwide. In our study, ST357 MDR/carbapenem-susceptible strains were isolated from the NICU. Our results emphasize that investigations should be performed not only on carbapenem-resistant but also on carbapenem-susceptible MDR *A. baumannii* isolates for studying the nosocomial infections and outbreaks caused by this organism.
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###### 

Clinical characteristics of 8 patients infected with multidrug-resistant *A. baumannii* strains isolated in a neonatal intensive care unit
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Abbreviations: GA, gestational age; RDS, respiratory distress syndrome.

###### 

Properties of multidrug-resistant *A. baumannii* strains isolated from a neonatal intensive care unit
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^\*^Indicates sense mutations at the 83rd residue (serine to leucine) in *gyrA* and at the 80th residue (serine to leucine or tryptophan) in *parC*.

Abbreviations: ST, sequence type; AMK, amikacin; GEN, gentamicin; CAZ, ceftazidime; FEP, cefepime; IPM, imipenem; CIP, ciprofloxacin; AMEs, aminoglycoside-modifying enzymes.
